Wolverine Trading’s Recursion Pharmaceuticals RXRX Stock Holding History

Wolverine Trading’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.15M	Buy	233,800 +60,100	+35%	+$316K	﹤0.01%	2754
2025 Q2	$874K	Sell	173,700 -11,000	-6%	-$54K	﹤0.01%	2441
2025 Q1	$1.07M	Sell	184,700 -88,800	-32%	-$647K	﹤0.01%	2173
2024 Q4	$1.85M	Buy	273,500 +171,900	+169%	+$1.16M	﹤0.01%	2035
2024 Q3	$709K	Buy	101,600 +31,900	+46%	+$229K	﹤0.01%	2706
2024 Q2	$523K	Sell	69,700 -6,800	-9%	-$59.3K	﹤0.01%	2807
2024 Q1	$763K	Buy	76,500 +56,100	+275%	+$625K	﹤0.01%	2442
2023 Q4	$201K	Buy	20,400 +6,100	+43%	+$43.5K	﹤0.01%	3872
2023 Q3	$109K	Buy	+14,300	New	+$143K	﹤0.01%	3972

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's RXRX Position: Q3 2025 in Review

Wolverine Trading increased its Recursion Pharmaceuticals (RXRX) stake by 26% in Q3 2025, buying an estimated $78.5K and bringing the position to 72,233 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #4135.

Wolverine Trading first reported a position in RXRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $598K in Q1 2025. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

Wolverine Trading held 72,233 shares of Recursion Pharmaceuticals worth $355K as of Q3 2025.
Wolverine Trading bought 14,954 Recursion Pharmaceuticals shares in Q3 2025, an estimated $78.5K.
Recursion Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4135 holding.
Wolverine Trading first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
Wolverine Trading's Recursion Pharmaceuticals position peaked at $598K in Q1 2025.
322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.